Leap Therapeutics, Inc. (LPTX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Leap Therapeutics reported revenue of $0. Net income was $4.8M, or $0.07 per diluted share. Operating activities generated -$43.9M of cash. At fiscal year end, Leap Therapeutics held $163.2M in total assets against $9.7M in total liabilities, including $14.0M of cash and equivalents.
Open the full interactive Leap Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Leap Therapeutics Key Stats
| Share Price | $2.84 |
|---|---|
| Market Cap | $617.3M |
| P/E Ratio | 40.6 |
| 52-Week Range | $0.41 – $4.12 |
| Shares Outstanding | 184.3 million (basic, 2026 Q2) |
Leap Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $1.5M | $1.5M | $0 | $0 | $0 | $0 |
| Operating Income | -$28.5M | -$41.4M | -$56.8M | -$87.0M | -$70.1M | -$41.1M |
| Pre-Tax Income | -$27.5M | -$40.6M | -$54.4M | -$81.4M | -$67.0M | $10.1M |
| Income Tax | -$2,000 | -$24,000 | $147,000 | — | $585,000 | $5.3M |
| Net Income | -$27.5M | -$40.6M | -$54.6M | -$81.4M | -$67.6M | $4.8M |
| Diluted EPS | -$6.30 | -$4.70 | -$4.80 | -$3.98 | -$1.81 | $0.07 |
Leap Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$3.3M | $40.2M | -$77.2M | $39.4M |
| Diluted EPS | -$0.08 | $0.57 | -$0.46 | $0.18 |
Leap Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $52.1M | $114.9M | $65.5M | $70.6M | $47.2M | $14.0M |
| Current Assets | $52.3M | $116.9M | $68.0M | $71.6M | $48.0M | $162.1M |
| Total Assets | $54.4M | $117.9M | $70.4M | $72.8M | $49.1M | $163.2M |
| Current Liabilities | $7.4M | $10.0M | $11.2M | $12.7M | $14.1M | $4.6M |
| Total Liabilities | $7.7M | $10.0M | $11.5M | $12.7M | $14.1M | $9.7M |
| Shareholders' Equity | $46.7M | $107.9M | $58.9M | $60.1M | $35.0M | $153.5M |
Leap Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$26.0M | -$35.2M | -$49.0M | -$43.8M | -$60.3M | -$43.9M |
| Cash From Investing | $25,000 | — | — | $49.0M | — | -$97.0M |
| Cash From Financing | $74.0M | $98.0M | -$210,000 | -$30,000 | $37.2M | $107.6M |
| Free Cash Flow | -$26.1M | — | — | — | — | — |
Figures from Leap Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Leap Therapeutics financials page for every line item.
Leap Therapeutics Company Profile
| Ticker | LPTX |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Cambridge, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001509745 |
Frequently Asked Questions
What was Leap Therapeutics' revenue in fiscal 2025?
Leap Therapeutics (LPTX) reported revenue of $0 for fiscal 2025.
What is Leap Therapeutics' annual revenue history?
Leap Therapeutics' annual revenue by fiscal year: 2020: $1.5M; 2021: $1.5M; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Leap Therapeutics' net income in fiscal 2025?
Leap Therapeutics reported net income of $4.8M for fiscal 2025.
What was Leap Therapeutics' earnings per share (EPS) in fiscal 2025?
Leap Therapeutics' diluted EPS was $0.07 for fiscal 2025 (adjusted for any later stock splits).
What was Leap Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Leap Therapeutics reported revenue of $0.
How many shares of Leap Therapeutics are outstanding?
Leap Therapeutics reported a weighted average of 184.3 million basic shares outstanding in 2026 Q2.
What is Leap Therapeutics' market cap?
Based on its latest closing price, Leap Therapeutics (LPTX) has a market capitalization of about $617.3M.
When does Leap Therapeutics' fiscal year end?
Leap Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Leap Therapeutics headquartered?
Leap Therapeutics lists its business address in Cambridge, Massachusetts in its SEC filings.